Effects of lipid lowering therapy on progression of coronary and carotid artery disease

Current Opinion in Lipidology

Volumn 8, Issue 6, 1997, Pages 354-361

  Ballantyne, Christie M ^a   Herd, J Alan ^a   Dunn, J Kay ^a   Jones, Peter H ^a   Farmer, John A ^a   Gotto Jr , Antonio M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; STATIN;

ANGIOGRAPHY; APHERESIS; ATHEROSCLEROSIS; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0030809899     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199712000-00006     Document Type: Review

References (45)

1. Kannel WB: Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995, 76:69C-77C.
2. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH, and the Harvard Atherosclerosis Reversibility Project (HARP) Group: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 1994, 344:1182-1186.
3. Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH, and the Harvard Atherosclerosis Reversibility Project Research Group: The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol 1995. 76(suppl):78C-85C.
4. West MS, Herd JA, Ballantyne CM, Pownall HJ, Simpson S, Gould KL, Gotto AM Jr, for the LCAS Investigators: The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials 1996, 17:550-583.
5. 1).
6. National Cholesterol Education Program: Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994, 89:1329-1445.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C et al., for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
8. 1. No benefit was observed with low-dose warfarin.
9. Thompson GR, Hollyer J, Waters DD: Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995, 6:386-388.
10. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lespérance M, the CCAIT Study Group: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89:959-968.
11. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI et al., and the MARS Research Group: Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993, 119:969-976.
12. MAAS Investigators: Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994, 344:633-638.
13. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME, for the PLAC I Investigators: Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995, 26:1133-1139.
14. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI, for the REGRESS Study Group: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540.
15. Watts GF, Burke V: Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol 1996, 7:341-355.
16. Yusuf S, Anand S: Cost of prevention: the case of lipid lowering. Circulation 1996, 93:1774-1776.
17. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849-853. Bezafibrate significantly slowed the progression of CAD in young men who had myocardial infarction before the age of 45 years, despite having only minimal effects on LDL-cholesterol levels, suggesting benefits related to triglyceride, HDL-cholesterol, and fibrinogen.
18. de Faire U, Ericsson C-G, Grip L, Nilsson J, Svane B, Hamsten A: Secondary preventive potential of lipid-lowering drugs: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996, 17 (suppl F):37-42.
19. Mack WJ, Krauss RM, Hodis HN: Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996, 16:697-704. Using analytical ultracentrifugation to distinguish lipoprotein subclasses, the MARS investigators found that smaller, denser lipoproteins were related to CAD progression.
20. Superko HR: Beyond LDL-cholesterol reduction [Editorial]. Circulation 1996, 94:2351-2354.
21. Tardif J-C, Côté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P, for the Multivitamins and Probucol Study Group: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997, 337:365-372. In a randomized trial, probucol with or without multivitamins was found to reduce restenosis 6 months after PTCA; multivitamins including antioxidants had no significant effect.
22. Regnström J, Walldius G, Nilsson S, Schäfer Elinder L, Johansson J, Mölgaard J, Holme l, Olsson AG, Nilsson J: The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis 1996, 125:217-229.
23. Kajinami K, Nishitsuji M, Takeda Y, Shimizu M, Koizumi J, Mabuchi H: Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. Atherosclerosis 1996, 120:181-187.
24. Kroon AA, Aengevaeren WRM, van der Werf T, Uijen GJH, Reiber JHC, Bruschke AVG, Stalenhoef AFH: LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93:1826-1835. In a randomized trial of simvastatin alone, or in combination with LDL apheresis, no additional coronary angiographic benefit was seen with LDL apheresis despite additional reductions in LDL-cholesterol and Lp(a).
25. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ et al.: Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995, 345:811-816.
26. Aengevaeren WRM, Kroon AA, Stalenhoef AFH, Uijen GJH, van der Werf T: Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease: the LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996, 28:1696-1704.
27. de Groot E, Jukema JW, van Boven AJ, Reiber JHC, Zwinderman AH, Lie KI, Ackerstaff RA, Bruschke AVG, for the REGRESS study group: Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. Am J Cardiol 1995, 76:40C-46C.
28. Kroon AA, van Asten WNJC, Stalenhoef AFH: Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996, 125:945-954. Simvastatin in combination with LDL apheresis led to regression of carotid artery lesions and prevented progression of peripheral artery lesions, whereas progression was seen in both vascular beds with simvastatin alone. Further LDL-cholesterol and Lp(a) reductions with apheresis gave greater benefit on carotid but not coronary artery disease progression.
29. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Alaupovic P, Kwong-Fu H, Azen SP: Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized, controlled clinical trial. Ann Intern Med 1996, 124:548-556.
30. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M et al.: Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996, 101:627-634.
31. Suurküla M, Agewall S, Fagerberg B, Wendelhag I, Wikstrand J, for the Risk Intervention Study (RIS) Group: Multiple risk intervention in high-risk hypertensive patients: a 3-year ultrasound study of intima-media thickness and plaques in the carotid artery. Arterioscler Thromb Vasc Biol 1996, 16:462-470.
32. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA et al., for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994, 90:1679-1687.
33. Grouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995, 75:455-459
34. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R. Park J-S, Salonen JT: Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995, 92:1758-1764.
35. Buchwald H, Matts JP, Fitch LU, Campos CT, Sanmarco ME, Amplatz K, Casteneda-Zuniga WR, Hunter DW, Pearce MB, Bissett JK, for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group: Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992, 268:1429-1433.
36. Waters D, Craven TE, Lespérance J: Prognostic significance of progression of coronary atherosclerosis. Circulation 1993, 87:1067-1075.
37. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH, Blankenhom DH, Hodis HN: Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996, 93:34-41.
38. Crouse JR III, Byington RP, Hoen HM, Furberg CD: Reductase Inhibitor monotherapy and stroke prevention. Arch Intern Med 1997, 157:1305-1310.
39. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997, 278:313-321. A meta-analysis of 16 trials of statin therapy indicated significant reductions of 29% in stroke incidence, 22% in total mortality and 28% in cardiovascular mortality.
40. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
41. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995, 91:2844-2850.
42. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJGM, Lie KI, Bruschke AVG, for the REGRESS Study Group: Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996, 94:1503-1505. In REGRESS, in which patients received conventional anti-ischemic medication as well as the randomized treatment, 1-year change from baseline in the percentage of patients with transient myocardial ischemia showed significant improvement with pravastatin.
43. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP: Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997, 95:324-328. In CAD patients with ischemia, 4 6 months of lovastatin treatment led to resolution of ST-segment depression in 65% of patients, compared with 10% of placebo patients.
44. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131.
45. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM: Levels of soluble cell adhesion molecules In patients with dyslipidemia. Circulation 1996, 93:1334-1338.